Skip to main content

Table 1 Prevalence of anemia in stage 3–5 NDD-CKD Patients in 20% Medicare and commercially insured (MarketScan) datasets

From: Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States

 

Medicare

Commercially insured (MarketScan)

  

Anemia prevalence (%), CKD stage

 

Anemia prevalence (%), CKD stage

Characteristics

n, anemiaa

3–5

3

4

5

n, anemiaa

3–5

3

4

5

Overall

109,251

50.1

43.9

64.0

72.8

15,716

28.0

22.4

41.3

53.9

Age, years

 18–44

─ ─

─ ─

─ ─

─ ─

─ ─

1724

25.9

19.6

34.9

50.4

 45–54

─ ─

─ ─

─ ─

─ ─

─ ─

3755

27.0

21.4

40.1

50.6

 55–59

─ ─

─ ─

─ ─

─ ─

─ ─

4450

28.5

23.0

41.5

56.4

 60–63

─ ─

─ ─

─ ─

─ ─

─ ─

5787

28.9

23.3

44.2

56.8

 66–69

15,500

44.6

38.0

59.9

69.0

─ ─

─ ─

─ ─

─ ─

─ ─

 70–74

25,212

47.0

40.7

62.5

70.9

─ ─

─ ─

─ ─

─ ─

─ ─

 75–79

29,625

50.1

44.2

63.6

72.9

─ ─

─ ─

─ ─

─ ─

─ ─

 80–85

38,914

55.1

49.2

67.0

76.5

─ ─

─ ─

─ ─

─ ─

─ ─

Sex

 Men

50,615

46.9

41.1

60.3

69.5

7531

23.7

18.5

35.1

50.5

 Women

58,636

53.2

46.7

67.4

76.2

8185

33.6

27.5

48.5

58.3

Raceb

 White

87,617

48.9

42.9

62.9

71.9

─ ─

─ ─

─ ─

─ ─

─ ─

 Black

15,263

57.9

51.0

70.5

75.2

─ ─

─ ─

─ ─

─ ─

─ ─

 Other

6371

51.4

43.5

66.4

75.1

─ ─

─ ─

─ ─

─ ─

─ ─

Comorbidity

 ASHD

57,070

59.0

53.0

70.0

78.4

3707

39.7

33.0

51.3

65.3

 CHF

44,239

66.9

61.1

74.9

82.4

3360

47.9

40.3

57.8

69.1

 CVA/TIA

25,814

62.6

56.9

73.1

79.8

1573

44.9

38.3

55.3

67.6

 PVD

38,868

62.8

57.0

72.2

80.6

2997

49.6

42.6

60.7

69.5

 Cardiac (other)

38,822

65.6

59.7

76.1

82.7

3688

48.5

41.5

60.7

67.9

 COPD

36,910

62.4

56.6

73.1

79.5

2467

43.5

37.6

54.1

67.2

 GI bleeding

13,773

87.1

83.9

92.4

93.3

1403

71.7

66.2

83.0

79.0

 Liver disease

4088

71.6

65.6

81.9

85.4

1118

52.2

44.9

60.5

70.3

 Dysrhythmia

47,814

61.1

55.3

71.3

79.7

3060

44.4

37.4

56.4

67.6

 Cancer

22,524

60.3

54.9

72.1

79.7

2227

41.7

35.3

57.8

69.2

 Diabetes

64,180

54.0

47.3

66.7

76.2

8246

33.7

27.4

46.4

59.1

 Hypertension

105,397

51.0

44.8

64.7

73.9

13,418

31.0

24.9

44.2

57.6

Inflammatory conditions

 Glomerulonephritis

6529

68.7

58.1

77.9

88.1

1229

44.1

34.7

52.8

75.0

 Chronic infections

2128

74.7

70.4

78.8

89.3

622

56.2

48.7

70.7

72.4

 Crohn’s disease

836

70.5

64.2

80.4

90.3

199

50.3

47.2

53.4

65.9

 Ulcerative colitis

912

71.4

66.4

82.4

87.7

176

55.0

48.9

62.0

83.8

 Hepatitis C

703

66.7

61.5

72.2

77.0

354

48.2

42.8

50.4

62.7

 Gout

17,862

59.0

50.8

70.5

80.8

1521

32.2

26.0

43.8

59.6

 Rheumatoid arthritis

5593

67.4

61.8

78.8

87.6

495

39.8

35.9

55.6

53.9

  1. ASHD atherosclerotic heart disease, CHF congestive/chronic heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVA/TIA cerebrovascular accident/transient ischemic attack, GI gastrointestinal, NDD non-dialysis-dependent, PVD peripheral vascular disease
  2. aIn the row “Overall,” n is the total number of patients with anemia. In other rows, n represents the number of anemia patients in each subgroup; for example, the n of 57,070 in the row “ASHD” represents the number of anemia patients with comorbid ASHD
  3. bRace variable is not available in the MarketScan database